Product Name: CIITA Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, IF, IHC-P, WB
Applications: CIITA antibody can be used for detection of CIITA by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: Predicted: 124 kDa Observed: 125 kDa
Immunogen: CIITA antibody was raised against a 16 amino acid synthetic peptide near the amino terminus of human CIITA.The immunogen is located within amino acids 120 – 170 of CIITA.
Host Species: Rabbit
Purification: CIITA Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 50-23-7
Product: Hydrocortisone
Buffer: CIITA Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: CIITA antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: CIITA Antibody: C2TA, NLRA, MHC2TA, CIITAIV, MHC class II transactivator, CIITA
Accession NO.: P33076
Protein Ino: 218511957
Official Symbol: CIITA
Geneid: 4261
Background: CIITA Antibody: CIITA contains an acidic transcriptional activation domain, four LRRs (leucine-rich repeats) and a GTP binding domain. It is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the master control factor for the expression of these genes. CIITA also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction.
PubMed ID:http://aac.asm.org/content/36/3/682.abstract
